Amgen Inc (AMGN)

Vertex Pharmaceuticals has successfully completed its acquisition of Crinetics Pharmaceuticals for an equity value of approximately $10.0 billion, enhancing its innovation pipeline with drugs like PALSONIFY and atumelnant, projected to generate over $5 billion in combined annual revenue. Concurrently, Vertex announced an expansion of its executive leadership, with Charles Wagner taking an expanded COO role, Jonathan Poole becoming the new CFO, and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer. These strategic moves aim to support Vertex's continued growth and diversification, establishing rare endocrine diseases as a new pillar of growth.

Jim Cramer highlighted Amgen's drug Repatha, suggesting its potential in the cardiovascular market could rival the scope of Eli Lilly's GLP-1 drugs, a market Cramer calls "the biggest of all time." Despite Wall Street largely overlooking Repatha, the drug saw significant Q2 sales growth of 37% year-over-year, reaching $953 million, and contributing to Amgen's substantial year-to-date stock rally. Cramer emphasizes Repatha's effectiveness in reducing heart attack and stroke risk, working against diabetes and high cholesterol, and benefiting from evolving medical practices promoting lower LDL cholesterol levels.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced that its management will participate in three investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. The company, a leader in masked, conditionally activated biologics, will present during fireside chats at each event, with live webcasts available on their website. Management will also be available for one-on-one meetings with registered investors.

The UK's medicines regulator has suspended Amgen's rare-disease drug, Tavneos, for new patients due to unreliable data from its main study, stating the trial could no longer prove the drug's efficacy or that its benefits outweighed the risks. The regulator plans to revoke UK approval on March 1, 2027, though current patients can continue treatment for six months while alternatives are considered. This decision follows similar actions by the European Commission and a proposed withdrawal by the U.S. FDA, which has also linked Tavneos to serious liver injuries.

The UK's medicines regulator has suspended Amgen's rare-disease drug, Tavneos, for new patients due to unreliable data from its main approval study. The regulator cited that the study can no longer prove the drug's effectiveness or that its benefits outweigh the risks, planning to revoke UK approval by March 1, 2027. Patients already on the drug can continue for six months, while regulatory bodies in Europe and the US have also questioned its efficacy and safety, including links to serious liver injuries and deaths.